black box warning for glp 1 agonists Glp1 and thyroid anomalies? : r/FamilyMedicine Liraglutide, the first long acting

doi: 10.1210/clinem/dgaa863 Summary Keywords obesity, insulin-resistance, Tirzepatide, pathophysiology, GIP, GLP - 1, clinical trials, arterial hypertension Citation Corrao S, Pollicino C, Maggio D, Torres A and Argano C (2024) Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence

[DOI] [PubMed] [Google Scholar] 28.Newsome P.N., Ambery P

This became known as the "incretin effect," which led researchers to hypothesize that some hormones released from the gut were enhancing insulin secretion

[DOI] [PubMed] [Google Scholar] 86.le Roux C.W., Astrup A., Fujioka K., Greenway F., Lau D.C.W., Van Gaal L

15 Potential Additional Benefits Several studies have investigated potential additional benefits of DPP-4 inhibitors, including microvascular and macrovascular effects, effects on blood pressure (BP) and weight, and risk of hypoglycemia

It also lowers glucagon secretion, slows stomach emptying, promotes satiety, and improves glucose disposal in peripheral tissues